Lyell Immunopharma (LYEL)

Executive Summary

Lyell Immunopharma is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies designed to achieve durable remissions in hard-to-treat cancers. Despite a challenging track record with several terminated or withdrawn trials (IMPT-514 in lupus, LYL797 in triple-negative breast cancer, LYL845 in melanoma), the company continues to advance two key programs: GCC19CART in colorectal cancer (Phase 1, recruiting) and LYL314 in relapsed/refractory non-Hodgkin lymphoma (Phase 1/2, recruiting). Additionally, Lyell initiated a Phase 3 trial (NCT07188558) combining multiple CAR-T products in large B-cell lymphoma in early 2026. The company's proprietary LyFE Manufacturing Center supports integrated discovery, manufacturing, and clinical development. However, prior setbacks and an early-stage pipeline limit near-term visibility, and Lyell must demonstrate proof-of-concept in its ongoing studies to regain investor confidence.

Upcoming Catalysts (preview)

• Q1 2027Initial data readout from GCC19CART Phase 1 trial in colorectal cancer25% success
• 2026Interim safety/efficacy data from LYL314 Phase 1/2 trial in non-Hodgkin lymphoma35% success